BOULDER, Colo., Apr 16, 2012 (BUSINESS WIRE) --Array BioPharma Inc. (NASDAQ: ARRY) today announced that Howard Holden,
Ph.D., has joined the Company as Vice President of Regulatory Affairs
and Quality Assurance. With over 25 years of experience in regulatory
affairs and compliance in the pharmaceutical / biotechnology industry,
Dr. Holden will lead regulatory affairs and quality assurance for
Array's pipeline of targeted small molecule drugs to treat cancer and
"Howard's lifetime of regulatory experience will help Array navigate the
FDA approval path for our proprietary programs," said Kyle Lefkoff,
Executive Chairman, Array BioPharma. "He will make an immediate
contribution as we move our pipeline into registration studies, and
we're all excited to have Howard on the Array team."
During his career, Dr. Holden has built and led regulatory and
compliance functions for programs from Investigational New Drug (IND)
applications to New Drug Applications (NDA), Biologics License
Applications (BLA), and Marketing Authorization Applications (MAA);
developed and implemented regulatory drug development and compliance
strategies; and obtained approval for several products in the U.S.,
Europe and Canada. From 2005 until 2012, Dr. Holden was Senior Vice
President of Regulatory Affairs and Compliance at Nereus
Pharmaceuticals. Prior to joining Nereus, Dr. Holden was Vice President
of Regulatory Affairs and Compliance at Stressgen Biotechnologies and
Ligand Pharmaceuticals, Senior Director at Parke-Davis/Warner-Lambert,
Director at Centocor and Senior Investigator at the National Cancer
Institute. Dr. Holden has over 120 publications on tumor immunology and
natural host resistance. Dr. Holden received his bachelor's degree from
Drew University and his Ph.D. in microbiology from the University of
Miami, School of Medicine.
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of targeted small-molecule
drugs to treat patients afflicted with cancer and inflammatory diseases.
Array has four core proprietary clinical programs: ARRY-614 for
myelodysplastic syndromes, ARRY-520 for multiple myeloma, ARRY-797 for
pain and ARRY-502 for asthma. In addition, Array has 10 partner-funded
clinical programs including two MEK inhibitors in Phase 2 clinical
trials: selumetinib with AstraZeneca and MEK162 with Novartis. For more
information on Array, please go to www.arraybiopharma.com.
SOURCE: Array BioPharma Inc.
Array BioPharma Inc.
Tricia Haugeto, 303-386-1193